2015 Fiscal Year Final Research Report
Development of new engineered CAR-T cells with the ability to block immune checkpoint pathways
| Project/Area Number |
25830118
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
SAKODA Yukimi 山口大学, 医学(系)研究科(研究院), 助教 (30629754)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 免疫療法 / キメラ抗原受容体 |
|---|
| Outline of Final Research Achievements |
The adoptive transfer of chimeric antigen receptor（CAR) T cells shows an impressive clinical efficacy against B-cell derived hematologic malignancies, while the efficacy against solid tumors have been much less encouraging. One possible explanation of its low efficacy is that solid tumor facilitates immune checkpoint pathways as an important immune resistance mechanism within the tumor microenvironment. In this study, we have shown that CAR-T cells engineered to possess the capacity to block an immune checkpoint pathway can induce strong anti-tumor responses.
|
| Free Research Field |
免疫学
|
